Major pharma companies, including AstraZeneca, Bristol Myers Squibb, and Sanofi, pursue deals in China amid U.S.-China tensions to strengthen drug pipelines and expand market presence.
Despite escalating U.S.-China tensions, major pharmaceutical companies such as AstraZeneca, Bristol Myers Squibb, and Sanofi are pursuing deals in China to strengthen their drug pipelines and expand their presence in the world's second-largest pharmaceutical market. Despite risks, including potential conflicts and economic downturns, the acquisitions of Chinese healthcare companies reached $6.8 billion by July 16, the lowest in a decade for the same period.
July 23, 2024
9 Articles